Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Neurocrine Biosciences reports strong Q4 performance and eyes growth

Neurocrine Biosciences delivered strong performance in Q4 2022, with robust INGREZZA sales and a positive outlook for 2023, supported by significant investments in SG&A and R&D.
The company's focus on expanding into long-term care, advancing pipeline assets, and collaborations for innovative treatments positions it well for growth and addressing unmet needs.
While facing challenges in managing increased spending and market dynamics, Neurocrine remains optimistic about opportunities in expanding treatment reach, market penetration, and advancing clinical programs.

Neurocrine Biosciences reports strong Q1 performance and eyes international expansion

Neurocrine Biosciences had a strong Q1 performance with record sales, upcoming milestones, and disciplined expense management.
The company faces challenges in certain therapeutic categories but is optimistic about addressing unmet needs and expanding internationally.
Opportunities lie in innovative science, market positioning, and portfolio expansion, positioning Neurocrine for future growth.
Addressing concerns around drug interactions, dosing strategies, and trial risks will be crucial for maintaining clinical success and patient safety.

Neurocrine Biosciences excels in Q2, eyes growth opportunities ahead

Neurocrine Biosciences shows strong financial performance and growth prospects.
Focus on INGREZZA's persistency and pipeline advancements drives optimism.
Challenges include market dynamics and clinical trial complexities.
Opportunities lie in new indications, long-term care expansion, and telemedicine.

Neurocrine Biosciences excels in Q3, eyes growth in LTC segment

Neurocrine Biosciences delivered a strong Q3 performance with robust sales, positive regulatory developments, and promising pipeline advancements.
The company's focus on expanding indications, exploring combination therapies, and addressing market opportunities positions it for future growth.
While facing challenges in market evaluation and competition, Neurocrine Biosciences has opportunities to leverage its strengths and drive innovation.
Investors can look forward to upcoming events like the Analyst Day and R&D Day for deeper insights into the company's strategic direction and growth potential.

Neurocrine Biosciences excels in 2023, eyes Crinecerfont launch success

Neurocrine Biosciences had a strong 2023 with notable achievements in sales growth and pipeline advancements. While facing challenges in market dynamics and pricing negotiations, the company is well-positioned to leverage opportunities in upcoming launches and strategic growth initiatives.

Neurocrine Biosciences excels in Q1 with strong sales and pipeline advancements

Neurocrine Biosciences delivered a strong performance in Q1 2024, driven by robust INGREZZA sales, promising Phase II results for NBI-845, and advancements in Crinecerfont development.
The company's strengths lie in its diverse pipeline, financial stability, and strategic focus on chronic therapy and tolerability, positioning it for future growth and innovation.
While facing challenges in dosing optimization and revenue management, Neurocrine has opportunities to leverage its pipeline, explore new treatments, and differentiate its offerings in the market.

Neurocrine Biosciences excels in Q3, poised for growth ahead

Neurocrine Biosciences showcased robust performance in Q3, with strong INGREZZA sales and pipeline success, positioning for future growth.
The company's strengths lie in its expanded sales team, leadership quality, and commitment to innovation and value creation for shareholders.
Challenges include potential payer reimbursement issues, FDA interactions for Phase III strategy, and competitive pressures in the market.
Opportunities abound with upcoming regulatory approvals, pipeline advancements, and targeted commercial strategies for new product launches.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

SAN DIEGO , Jan. 3, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 41st Annual J.P. Morgan Healthcare Conference at 11:15 a.m.

Neurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Prescription Drug User Fee Act (PDUFA) Target Action Date Set for August 20, 2023 SAN DIEGO , Dec. 22, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for valbenazine as a treatment for chorea associated with Huntington disease (HD). The agency set a Prescription Drug User Fee Act (PDUFA) target action date of August 20, 2023.

Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease

SAN DIEGO , Dec. 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that investigational NBI-827104 did not meet its primary endpoint in the Phase 2 STEAMBOAT™ study evaluating the efficacy, safety, tolerability and pharmacokinetics of NBI-827104 compared to placebo in pediatric patients with epileptic encephalopathy with continuous spike-and-wave during sleep (EE-CSWS). NBI-827104 was generally well tolerated.

Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep

SAN DIEGO , Dec. 2, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc.   (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported demographic and clinical characteristics data from genetic screening-based studies of children with SCN8A-related epilepsies. Data was collected from more than 17,000 patients through Invitae Corporation's Behind the Seizure® Program, of which Neurocrine Biosciences is a sponsor.

Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022

Catalyst Pharmaceuticals

Genmab - ADR

Harmony Biosciences Holdings

Top biotech stocks surge within the IBD 50. Some pass buy points while others build bases.

Hot Biotech Stocks Rise Into Leadership; Pass Buy Points Or Build Bases

Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday's high of $125.99. It is forming a bullish channel.

Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?

SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences: Kevin Gorman, Chief Executive Officer, Matt Abernethy, Chief Financial Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will present at the Jefferies London Healthcare Conference at 1:30 p.m. Greenwich Mean Time (8:30 a.m.

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.

3 Reasons Growth Investors Will Love Neurocrine (NBIX)

SAN DIEGO , Nov. 3, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data from a study on INGREZZA® (valbenazine) capsules evaluating in vitro dissolution performance of whole intact or crushed capsule contents in 40 mg and 80 mg strength. These data (Poster #27, Complete In Vitro Dissolution of Valbenazine as Either Whole Capsule or Crushed Content) are being shared at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting being held on November 3-6 in San Antonio, Texas.

Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsules at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting

SAN DIEGO , Nov. 3, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported additional results from the Phase 3 KINECT-HD study investigating valbenazine for the treatment of chorea associated with Huntington Disease (HD). In December 2021, Neurocrine previously reported that once-daily administration of valbenazine was well tolerated with a statistically significant improvement in chorea associated with HD compared with placebo, along with substantial clinician- and patient-rated global improvement.

Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2022 Earnings Conference Call November 1, 2022 8:00 AM ET Company Participants Todd Tushla - VP of IR Kevin Gorman - CEO Matt Abernethy - CFO Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Kyle Gano - Chief Business Development & Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Paul Matteis - Stifel Phil Nadeau - Cowen & Company Neena Bitritto-Garg - Citi Anupam Rama - JPMorgan Brian Abrahams - RBC Capital Markets Carter Gould - Barclays Chris Shibutani - Goldman Sachs Myles Minter - William Blair Brian Skorney - Baird Laura Chico - Wedbush Ashish Sharma - UBS Jeff Hung - Morgan Stanley Jay Olson - Oppenheimer Marc Goodman - SVB David Amsellem - Piper Sandler Uy Ear - Mizuho Securities Conor MacKay - BMO Capital Markets Yatin Suneja - Guggenheim Partners Mohit Bansal - Wells Fargo Sumant Kulkarni - Canaccord Genuity Operator Good day, everyone. And welcome to today's Neurocrine Biosciences Reports Third Quarter Results.

Neurocrine Biosciences, Inc. (NBIX) Q3 2022 Earnings Call Transcript

Neurocrine (NBIX) delivered earnings and revenue surprises of -17.86% and 2.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Q3 Earnings Lag Estimates

Neurocrine Biosciences beat third-quarter forecasts and raised its Ingrezza outlook for 2022, leading NBIX stock to jump Tuesday. The post Blazing Hot Neurocrine Biosciences, With 35% Run This Year, Extends Breakout On Quarterly Beat appeared first on Investor's Business Daily.

Blazing Hot Neurocrine Biosciences, With 35% Run This Year, Extends Breakout On Quarterly Beat

INGREZZA® (valbenazine) Third Quarter Net Product Sales of $376 Million INGREZZA® (valbenazine) 2022 Net Product Sales Guidance Raised to $1.4 - $1.425 Billion Supplemental New Drug Application (sNDA) of Valbenazine For the Treatment of Chorea in Patients with Huntington Disease Submitted to the U.S. Food and Drug Administration SAN DIEGO , Nov. 1, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2022 and raised net sales guidance for INGREZZA in 2022. "INGREZZA continues to help more and more patients who suffer from tardive dyskinesia.

Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance

TOKYO and CAMBRIDGE, United Kingdom, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, notes its partner Neurocrine Biosciences Inc. (“Neurocrine”) announced the first patient has been randomized for its Phase 2 placebo-controlled, inpatient clinical study evaluating the efficacy, safety, tolerability, and pharmacokinetics of investigational compound NBI-1117568 in adults with schizophrenia. NBI-1117568 is an investigational, muscarinic M4 selective acetylcholine receptor agonist believed to be a key regulator of neurotransmitters impacted by schizophrenia.

Sosei Heptares' Partner Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia

NBI-1117568 is an Investigational, First-in-Class, Muscarinic M4 Selective Agonist SAN DIEGO , Oct. 27, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced the first patient has been randomized for its Phase 2 placebo-controlled, inpatient clinical study evaluating the efficacy, safety, tolerability, and pharmacokinetics of investigational compound NBI-1117568 in adults with schizophrenia. NBI-1117568 is an investigational, muscarinic M4 selective acetylcholine receptor agonist believed to be a key regulator of neurotransmitters impacted by schizophrenia.

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia

SAN DIEGO , Oct. 24, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented data detailing the baseline characteristics of patients with Parkinson's disease (PD) in the Opicapone Treatment Initiation Open-Label Study (OPTI-ON). The poster (Poster #M193); Parkinson's Disease Patient Characteristics in a U.S. Real-World Study of Opicapone) was presented at the 2022 American Neurological Association Annual Meeting (ANA2022) being held October 22–25.

Neurocrine Biosciences Presents Real-World Parkinson's Disease Patient Characteristics From ONGENTYS® (opicapone) Open-Label Study at ANA2022

SAN DIEGO , Oct. 19, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced data on the real-world comorbidities, polypharmacy, and treatment patterns of patients on newly prescribed benztropine who were also being treated with antipsychotic medications. This research will be presented at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference being held October 19–22 both virtually and in Long Beach, CA.

Neurocrine Biosciences Presents Data on Benztropine Use Among People Treated with Antipsychotics at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference

Conference Call and Webcast Scheduled for Tuesday, November 1 SAN DIEGO , Oct. 11, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m.

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2022 Financial Results

Cardinal Health

DoubleVerify Holdings

Cheniere Energy

Paylocity Hlds

Shockwave Medical

Vertex Pharmaceuticals

Wolfspeed

As the market indexes work through a downturn, Vertex is among nine stocks to watch showing relative strength. The post Vertex Among 9 Stocks To Watch In Struggling Market appeared first on Investor's Business Daily.

Vertex Among 9 Stocks To Watch In Struggling Market

As the market indexes work through a downturn, Vertex is among eight stocks to watch showing relative strength. The post Vertex Among 8 Stocks To Watch In Struggling Market appeared first on Investor's Business Daily.

Vertex Among 8 Stocks To Watch In Struggling Market

SAN DIEGO , Sept. 29, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that Dr. Ingrid Delaet will join the company's executive management team as Chief Regulatory Officer effective October 1, leading the regulatory affairs, quality assurance, medical writing, and program management teams.

Neurocrine Biosciences Appoints Dr. Ingrid Delaet as Chief Regulatory Officer

Humana

Eli Lilly

McKesson

S&P 500 giant Eli Lilly leads five medical stocks setting up and showing relative strength in the ongoing bear market. The post S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market appeared first on Investor's Business Daily.

S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market

SAN DIEGO , Sept. 19, 2022  /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data demonstrating sustained improvements with long-term INGREZZA® (valbenazine) capsules treatment in adults with tardive dyskinesia (TD) at the Psych Congress 2022 scientific meeting being held September 17-20.

Neurocrine Biosciences Presents INGREZZA® (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022

Devon Energy

Enphase Energy

First Solar

JinkoSolar Holding

Palo Alto Networks

STAAR Surgical

Invesco Solar ETF

S&P 500 dividend standout Devon Energy leads this weekend's watch list of stocks near buy points in a tough market. The post S&P 500 Dividend Standout Leads 5 Resilient Stocks Near Buy Points As Fed Looms appeared first on Investor's Business Daily.

News for Neurocrine Biosciences Stock (NBIX)